What Almogran Treats: Main Uses and Benefits

Almogran (Almotriptan) is a specialized prescription agent applied across domains where additional symptomatic support is needed during the active, acute phase of a migraine episode. It is generally not used for preventing future headaches but for managing the symptomatic course of an attack once it has begun. The medication is intended for use in contexts marked by increased discomfort associated with these episodes.

---

Therapeutic Scope and Benefits

Almogran is commonly used for established migraine headaches presenting with moderate or severe pain intensity. It is relevant for managing the symptoms of migraine with aura and migraine without aura, as well as specific scenarios like menstrual migraine and attacks in adolescents (aged 12 to 17 years). It helps address symptom clusters that may become intense or disruptive, specifically the throbbing head pain, the accompanying nausea, and sensory hypersensitivity, including photophobia and phonophobia.

A general benefit is that Almogran offers symptomatic relief that helps patients cope more steadily with difficult episodes.

---

Quick Fact: Supportive Management for Acute Migraine Symptoms

Property	Description
Target Conditions	Migraine with aura, migraine without aura
Symptom Intensity	Moderate to severe pain
Primary Support Goals	Easing head pain, managing nausea, addressing sensitivity to light and sound
Therapeutic Focus	Short-term symptomatic assistance during acute episodes

Regulatory References

1. NIH MedlinePlus Drug Information on Almotriptan

Almogran (Almotriptan) eligibility is strictly defined by regulatory authorities based on age and pre-existing medical conditions, establishing groups who may or must not use the medicine.

Approved Populations

Age Group	Eligibility Status
Adults	Standard approved use.
Adolescents	Approved for those 12 to 17 years of age.
Children (<12)	Safety and effectiveness not established.
Older Adults (>65)	Use with caution due to insufficient safety data.

Absolute Contraindications

Almogran is strictly prohibited for patients with a history of Ischemic Heart Disease (e.g., myocardial infarction, angina pectoris) or Coronary Artery Vasospasm. It is also contraindicated for those with uncontrolled hypertension, Cerebrovascular Syndromes (e.g., stroke, TIA), Severe Hepatic Impairment, and specific migraine subtypes (Hemiplegic or Basilar).

Conditional Use

Patients with Severe Renal Impairment or Mild to Moderate Hepatic Impairment must have their use restricted to a limited maximum daily dose. Use is also contraindicated within 24 hours of taking another triptan or an ergotamine-type medication.

The official regulatory profile for Almogran (Almotriptan) is defined by specific pharmacokinetic and pharmacodynamic constraints with other products.

Interaction scope

Category	Description
Medicinal product categories with documented interactions	Other 5-HT1B/1D Receptor Agonists (Triptans); Ergotamine-containing or Ergot-type medications; Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Potent CYP3A4 Inhibitors; Monoamine Oxidase Inhibitors (MAOIs).
Timing-based interaction rules (if applicable)	Must not be administered within 24 hours of co-administration of any other 5-HT1B/1D agonist or ergot-type medication.
Population-specific interaction notes (if applicable)	Treatment is contraindicated in patients with severe hepatic impairment. Dosage must be strictly limited when co-administered with potent CYP3A4 inhibitors in patients with renal or hepatic impairment.

---

Interaction classifications (high-level)

Category	Classification Details (as defined in official documents)
Interaction severity classification	Contraindicated (e.g., other Triptans, Ergotamine); Risk of Serious Reaction (e.g., Serotonin Syndrome with SSRIs/SNRIs); Clinically Significant Exposure Increase (e.g., ~60% increase with potent CYP3A4 inhibitors like Ketoconazole).

---

Resulting interaction structure

Official regulatory documents establish that co-administration with other Triptans or Ergotamine derivatives is contraindicated due to the theoretical risk of additive vasospastic effects. This requires a mandatory 24-hour separation window. Pharmacodynamic risks involve potential Serotonin Syndrome when combined with SSRIs or SNRIs. Furthermore, potent CYP3A4 inhibitors (e.g., Ketoconazole) officially increase Almotriptan plasma exposure by approximately 60%, necessitating dose restrictions to manage the increased systemic concentration.

How Almogran Works: Mechanism of Action

---

Targeted Agonism at Serotonin 5-HT1B/1D Receptors

Almogran (Almotriptan) is a selective and high-affinity agonist (activator) of the 5-HT1B and 5-HT1D receptors situated within the cranial neurovascular unit. This dual action initiates physiological changes by targeting both vascular structures and afferent nerve terminals.

---

Dual Modulation of the Trigeminovascular System

The activation of 5-HT1B receptors on arterial smooth muscle causes vasoconstriction of the abnormally dilated extracerebral blood vessels, promoting the normalization of the vascular diameter. Concurrently, activation of 5-HT1D receptors on presynaptic trigeminal nerve endings inhibits the release of pro-inflammatory neuropeptides, notably Calcitonin Gene-Related Peptide (CGRP). This inhibitory action dampens the signaling cascade that promotes neural sensitization.

---

Physiological Consequence

The physiological outcome relies on the combined effect of vascular stabilization and neuronal signal dampening. This dual mechanism acts to interrupt the signaling patterns within the overactive trigeminovascular pathway, modifying the progressive sequence of the ongoing event.

Almogran is an oral medicine administered as film-coated tablets available in strengths of 6.25 mg and 12.5 mg of almotriptan. Its clinical application is restricted to the acute treatment of established migraine headaches and is not indicated for migraine prevention. The standard procedure involves taking the medicine as early as possible following the onset of the migraine, regardless of food intake, swallowing the tablet whole with liquid.

The general adult initial dose is either 6.25 mg or 12.5 mg. The maximum single dose is 12.5 mg, and the total dose administered must not exceed 25 mg within any 24-hour period. If the initial dose provides relief but the headache recurs, a single second dose may be taken after a minimum interval of 2 hours. The drug is not intended for a second dose during the same attack if the first tablet provided no therapeutic response.

Usage parameters vary for patients with certain conditions. For example, individuals with severe hepatic or renal impairment have a maximum daily dose ceiling of 12.5 mg. Similarly, for adolescents aged 12 to 17 years, the recommended single dose is also 6.25 mg or 12.5 mg. The safety of treating more than four migraine headaches in a 30-day period has not been established in clinical practice.

Research evidence / Overview of studies for Almogran

The core evidence for Almogran's use for the acute treatment of migraine in adults primarily uses randomized, double-blind, placebo-controlled trials (RCTs). These studies are conducted during periods of increased symptom activity, and their findings describe patterns observed in the study populations. In these trials, researchers examined outcomes related to physical discomfort and episodic evolution in symptoms, such as the achievement of pain-free status or reduction in pain intensity two hours after taking the medicine.

These core studies also monitored secondary outcomes describing the patient-reported experience, such as the assessment of sustained pain-free status, which is an endpoint tracking the absence of headache recurrence within 24 hours. Research explored outcomes related to the absence of associated symptoms, including outcomes related to the absence of nausea, photophobia (light sensitivity), and phonophobia (sound sensitivity) at the two-hour mark. Findings indicate patterns related to short-term evolution of these symptoms when Almogran was evaluated in populations experiencing moderate to severe migraine attacks.

---

Evidence for Use in Adolescent Migraine

Almogran was studied for the acute treatment of migraine in the adolescent population (ages 12 to 17 years) through mandated pediatric study commitment trials and controlled studies. This research examined short-term symptom evolution, focusing on episodes where symptoms become more noticeable. Study outcomes measured included the achievement of pain-free status or pain intensity reduction at the primary two-hour assessment point.

---

What Remains Uncertain in the Research

Research so far indicates several areas where data remain insufficient or uncertain. There is limited information for long-term outcomes derived from controlled, comparative trials, with most extended-duration data coming from open-label, non-comparative use documentation. Evidence is limited for managing acute attacks in patients diagnosed with chronic or high-frequency migraine. Similarly, patients with certain complicated migraine types (such as hemiplegic or basilar migraine) were typically excluded from the main controlled studies.

Key Studies & References

1. Almotriptan increases sustained pain-free outcomes in acute migraine: Results from three controlled clinical trials

Common questions about Almogran (FAQ)

Q: Does Almogran cause rebound headaches (medication-overuse headache)?

Official documentation describes a risk that using acute migraine treatment too frequently can lead to a condition known as medication-overuse headache. This condition is characterized by headaches occurring more often or becoming worse over time. Regulatory information outlines specific frequency limits to mitigate this risk.

Q: Are there any long-term safety concerns associated with using Almogran frequently?

Regulatory guidance indicates that the safety of treating more than four migraine headaches in a 30-day period has not been established. This frequency limit is noted because using the medication too often may increase the risk of developing medication-overuse headache.

Q: Can I take Almogran for tension headaches?

Almogran is specifically indicated for the acute treatment of established migraine headaches. Official product information states that this medicine should not be used to treat common tension headaches or any other type of headache. It is intended only for diagnosed migraines.

Q: What general health conditions might make a person ineligible for Almogran?

According to official warnings, certain serious health conditions prevent the use of this drug, known as contraindications. These include severe or uncontrolled high blood pressure and a history of heart disease, stroke, or transient ischemic attack (TIA).

Q: Is Almogran typically prescribed for children or adolescents?

Official product information states that Almogran is indicated for the acute treatment of migraine headache pain in adolescents aged 12 to 17 years. However, the safety and effectiveness of the medicine have not been established in children under 12 years of age.

Q: Can Almogran be used if a migraine has been ongoing for several hours?

Regulatory documents indicate that the medicine is meant to be taken as early as possible following the onset of a migraine attack. While there is no explicit prohibition against taking it several hours later, the effectiveness of the drug may be reduced if it is taken late.

Q: What is the recommended interval between doses of Almogran?

Official regulatory documents define the minimum interval required between doses of this medicine. If initial relief is obtained and the headache symptoms return, a second dose may be considered only after a minimum interval of 2 hours has passed.

Q: Is Almogran used for migraines with aura or without aura?

The official prescribing information indicates that Almogran is intended for the acute treatment of migraine attacks in adults and adolescents. This includes migraines with or without an aura, which refers to the visual or sensory disturbance some people experience before the headache begins.

Q: What official warnings are associated with Almogran?

Official product warnings highlight several serious risks associated with using this drug. These include the potential for serious cardiovascular events (like heart attack or stroke), blood vessel problems, and the risk of Serotonin Syndrome when combined with certain other medicines.

Q: What are the contraindications listed in official documents for Almogran use?

According to the official product information, Almogran is contraindicated (should not be used) if a person has certain pre-existing conditions. These include ischemic heart disease, uncontrolled severe high blood pressure, and certain rare types of migraine like basilar or hemiplegic migraine.

Q: What happens if I take Almogran too often?

Official information states that using this medicine more often or for longer than recommended can cause headaches to become worse or more frequent. This worsening of symptoms is identified as medication-overuse headache.

Q: Is Almogran an abortive treatment for migraines?

Regulatory documents refer to this medicine as an acute treatment for established migraine attacks. This classification means the medicine is used to stop or 'abort' a migraine attack that is already in progress, rather than preventing future attacks.

Q: How quickly does Almogran typically start to work on a migraine?

Pharmacokinetic data from regulatory studies show that the active ingredient is typically absorbed after taking the oral tablet. Maximum concentrations in the blood are generally observed between 1.5 and 4 hours after administration.

Q: What is the expected duration of action for Almogran?

Official pharmacokinetic data provides context on how long the substance stays in the body. The biological half-life of almotriptan is approximately 3 hours.

Q: What are the most commonly reported side effects of Almogran?

According to official product information, the most commonly reported side effects include nausea, dry mouth, and dizziness. Other commonly reported effects are general numbness, tingling (paresthesia), and drowsiness.

Q: Is feeling dizzy or drowsy a common side effect of Almogran?

Official regulatory documents list dizziness and drowsiness (somnolence) among the common side effects. This potential effect is noted in the regulatory warnings section.

Q: Why do some people experience chest or throat tightness after taking Almogran?

Official warnings note that feelings of tightness, pain, pressure, or heaviness in the chest, throat, neck, or jaw are potential serious side effects. The official information advises patients experiencing these symptoms to seek prompt medical attention to rule out cardiovascular causes.

Q: Can Almogran safely be taken with commonly prescribed SSRI or SNRI antidepressants?

Official drug interaction warnings indicate that combining Almogran with certain antidepressants, such as SSRIs or SNRIs, carries a risk. This combination can lead to a potentially serious condition known as Serotonin Syndrome.

Q: What are the known drug-drug interactions for Almogran?

Regulatory warnings highlight several potential drug-drug interactions. Almogran should not be used within 24 hours of taking other triptans or ergot-type medications. There is also a known risk of Serotonin Syndrome when used with certain antidepressants.

Q: Does Almogran interact with herbal supplements like St. John's wort?

Official regulatory warnings indicate that the use of Almogran with St. John’s wort (a common herbal supplement) can increase the risk of Serotonin Syndrome.

Q: Is Almogran generally suitable for older adults?

Official product information notes that safety and effectiveness data are limited for individuals 65 years of age and older. Use in this age group typically requires careful monitoring and may involve a lower dose.

Q: Can someone with a history of high blood pressure use Almogran?

According to official contraindications, this medicine should not be used by patients with uncontrolled hypertension (high blood pressure). If blood pressure is medically controlled, regulatory guidance suggests use may still require close monitoring.

Q: What does the term 'triptan sensation' mean for patients using Almogran?

While the term 'triptan sensation' is not formally defined in official documents, common side effects are listed that align with this concept. These include feelings of heaviness or pressure, tingling (paresthesia), and tightness in the chest, throat, neck, or jaw.

Q: What is the connection between Almogran and serotonin levels in the body?

Almogran is categorized as a selective serotonin receptor agonist. Its therapeutic action is linked to serotonin, specifically by binding to 5-HT1B/1D receptors to help narrow blood vessels that may have become dilated during a migraine attack.

Q: Has Almogran been studied for use during pregnancy or breastfeeding?

Official regulatory guidance indicates it is not known whether the drug will harm an unborn baby or if it passes into breast milk. Regulatory information advises discussing the potential benefits and risks with a healthcare provider.

Q: Are there any known issues with Almogran and operating machinery?

Official warnings state that Almogran may cause drowsiness or dizziness, which has the potential to impair thinking or reactions. This effect is noted to potentially affect the safe operation of machinery or driving.

Q: Does Almogran affect blood pressure or heart rate?

Regulatory documents list potential adverse effects on the cardiovascular system. Use of this drug may cause an increase in blood pressure and changes in heart rhythm, such as palpitations (feeling like a racing heart) or tachycardia.

Q: Why is it important to confirm a migraine diagnosis before using Almogran?

Official product labeling emphasizes that this medicine is indicated only after a clear diagnosis of migraine has been established by a medical professional. This is required because the drug is not intended for use with other types of headaches.

Q: Does Almogran treat the underlying cause of the migraine or just the symptoms?

This medicine is an acute treatment designed to relieve the symptoms of an established migraine attack. Official documents clarify that it is not preventative and does not stop future migraine attacks from occurring.

Q: What should I know about the safety profile of Almogran?

The official safety profile for Almogran includes warnings about the potential for serious cardiovascular events (e.g., heart attack, stroke), cerebrovascular issues, and the risk of Serotonin Syndrome when combined with certain other medicines. There is also a warning about medication overuse headache.

Q: How does the route of administration (e.g., tablet) affect Almogran's onset of action?

Almogran is an oral tablet, and its pharmacokinetics describe how it works in the body. The time it takes for the drug to reach its maximum concentration in the blood (Tmax) is typically 1.5 to 4 hours.

Q: What is the guidance on using Almogran for 'silent' migraines without pain?

The medicine is indicated for the acute treatment of migraine attacks that occur with or without an aura. Official indications focus on the diagnosed migraine attack itself, which may include symptoms other than pain, such as aura.

Q: What specific type of headaches is Almogran NOT recommended for?

Official regulatory documents specify the types of headaches that Almogran is not recommended for. These include cluster headache, basilar migraine, and hemiplegic migraine, in addition to common tension headaches.

Q: Does Almogran cause any changes in weight?

According to data in regulatory documents, weight loss has been reported as a rare or uncommon side effect of this medicine.

How to Store and Dispose of Almogran (Almotriptan Malate)

Required Storage Conditions

Almogran tablets must be stored at Controlled Room Temperature, which is defined in regulatory labeling as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and kept in its original container for stability purposes. A mandatory requirement is to keep the medicine out of the reach of children.

Official Disposal Instructions

Unused or expired Almogran should be discarded according to official instructions. The preferred method is to use a dedicated drug take-back program. If a program is unavailable, the tablets may be disposed of in household trash after being mixed with an undesirable substance, such as coffee grounds or dirt, and placed in a sealed bag. This medicine must not be flushed down a toilet or sink.